DE69936527D1 - Verwendung von modifiziertem lysozyme c in der herstellung von pharmazeutika zur krankheitsbehandlung - Google Patents

Verwendung von modifiziertem lysozyme c in der herstellung von pharmazeutika zur krankheitsbehandlung

Info

Publication number
DE69936527D1
DE69936527D1 DE69936527T DE69936527T DE69936527D1 DE 69936527 D1 DE69936527 D1 DE 69936527D1 DE 69936527 T DE69936527 T DE 69936527T DE 69936527 T DE69936527 T DE 69936527T DE 69936527 D1 DE69936527 D1 DE 69936527D1
Authority
DE
Germany
Prior art keywords
sub
lysocyme
pharmaceuticals
manufacture
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69936527T
Other languages
English (en)
Other versions
DE69936527T2 (de
Inventor
Paolo Alberto Veronesi
Pablo E Rodriguez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Therapicon SRL
Original Assignee
Therapicon SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapicon SRL filed Critical Therapicon SRL
Publication of DE69936527D1 publication Critical patent/DE69936527D1/de
Application granted granted Critical
Publication of DE69936527T2 publication Critical patent/DE69936527T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462Lysozyme (3.2.1.17)
DE69936527T 1998-05-22 1999-05-20 Verwendung von modifiziertem lysozyme c in der herstellung von pharmazeutika zur krankheitsbehandlung Expired - Fee Related DE69936527T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT98MI001148A ITMI981148A1 (it) 1998-05-22 1998-05-22 Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie
ITMI981148 1998-05-22
PCT/IT1999/000142 WO1999061593A1 (en) 1998-05-22 1999-05-20 USE OF MODIFIED LYSOZYME c TO PREPARE MEDICINAL COMPOSITIONS FOR THE TREATMENT OF SOME SERIOUS DISEASES

Publications (2)

Publication Number Publication Date
DE69936527D1 true DE69936527D1 (de) 2007-08-23
DE69936527T2 DE69936527T2 (de) 2008-03-13

Family

ID=11380089

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69936527T Expired - Fee Related DE69936527T2 (de) 1998-05-22 1999-05-20 Verwendung von modifiziertem lysozyme c in der herstellung von pharmazeutika zur krankheitsbehandlung

Country Status (10)

Country Link
US (3) US7229809B2 (de)
EP (1) EP1105467B9 (de)
JP (1) JP2002516087A (de)
AT (1) ATE366804T1 (de)
AU (1) AU4163199A (de)
DE (1) DE69936527T2 (de)
ES (1) ES2292244T3 (de)
IT (1) ITMI981148A1 (de)
PT (1) PT1105467E (de)
WO (1) WO1999061593A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI981148A1 (it) * 1998-05-22 1999-11-22 Therapicon Srl Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie
JP2005047844A (ja) * 2003-07-28 2005-02-24 Hiroshi Yamazaki 生物由来高分子物質の分解物、これを含む食品、化粧品、及び医薬品並びにそれらの製造方法
ITMI20052327A1 (it) * 2005-12-06 2007-06-07 Therapicon Srl Lisozima umano ricombinante modificato
EP2254591B1 (de) 2008-02-08 2017-07-26 Prothera, Inc. Hemmung und behandlung von gastrointestinalen biofilmen
US9931381B2 (en) 2009-11-23 2018-04-03 Prothera, Inc. Methods of comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions
WO2014152678A1 (en) 2013-03-15 2014-09-25 University Of Massachusetts Compositions and methods for delivering agents to the central nervous system
CN109528498B (zh) * 2018-12-30 2021-05-18 美釉(西安)生物技术有限公司 一种用于深入封闭牙小管并防止生物膜形成的牙齿脱敏剂
WO2021012789A1 (zh) * 2019-07-19 2021-01-28 广州新创忆药物临床研究有限公司 含溶菌酶的药物组合物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
PL173978B1 (pl) * 1992-07-13 1998-05-29 Nika Health Products Ltd Sposób oddziaływania na wydzielanie cytokin w hodowli limfocytów krwi obwodowej
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
WO1995013090A1 (en) * 1993-11-10 1995-05-18 Enzon, Inc. Improved interferon polymer conjugates
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
ITMI981148A1 (it) * 1998-05-22 1999-11-22 Therapicon Srl Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie

Also Published As

Publication number Publication date
ITMI981148A1 (it) 1999-11-22
EP1105467A1 (de) 2001-06-13
WO1999061593A1 (en) 1999-12-02
US7012062B2 (en) 2006-03-14
AU4163199A (en) 1999-12-13
ATE366804T1 (de) 2007-08-15
JP2002516087A (ja) 2002-06-04
EP1105467B9 (de) 2008-02-13
EP1105467B1 (de) 2007-07-11
ES2292244T3 (es) 2008-03-01
US20030129181A1 (en) 2003-07-10
DE69936527T2 (de) 2008-03-13
PT1105467E (pt) 2007-08-13
US20030124110A1 (en) 2003-07-03
US20070086993A1 (en) 2007-04-19
US7229809B2 (en) 2007-06-12

Similar Documents

Publication Publication Date Title
IL126610A0 (en) N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3- one derivatives as factor xa inhibitors
ATE216360T1 (de) Sulfinsäurederivate und deren herstellung und verwendung
HUP9902341A2 (hu) Herpeszvírus elleni hatású fenil-tiazol-származékok, előállításuk és alkalmazásuk, a vegyületeket tartalmazó gyógyszerkészítmények
ES2151156T3 (es) Derivados de acidos n-(aroil)glicina hidroxamicos y compuestos relacionados.
BR0008015A (pt) Uso de um composto, composto, composições farmacêuticas, e, processo para preparar um composto
DE69519566D1 (de) Mittel zur kuenstliche braunung mit verbesserte farbe entwicklung
AU4064597A (en) Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
DE60231555D1 (de) Verbesserte synthese von polyanhydriden
CA2215695A1 (en) .beta.-sheet mimetics and use thereof as protease inhibitors
MY115211A (en) Novel amino acid derivatives, their preparation and use
DE69936527D1 (de) Verwendung von modifiziertem lysozyme c in der herstellung von pharmazeutika zur krankheitsbehandlung
HUP0001164A2 (hu) PF1022-ciklodepszipeptid-származékok
ES2007177A6 (es) Procedimiento para preparar amidas y tioamidas del acido 1'-desoxi-1'-(6-amino-9-purinil)-b-d-ribofuranuronico sustituidas en la posicion 2.
TR200000907T2 (tr) Nötrofil elastaz inhibitörleri olarak pirolopirolon türevleri.
BR9803914A (pt) Lantibióticos relacionados a actagardina e processos para sua preparação e uso.
CA2267945A1 (en) Anticonvulsant derivatives useful in treating neuropathic pain
CA2192786A1 (en) Cyclopeptolide inhibitors of adhesion molecules
EE9800141A (et) Amidiini ja isotiokarbamiidi derivaadid lämmastikoksiidi süntaasi inhibiitoritena
DK526087A (da) Antikonvulsive aminosyrederivater
ATE317263T1 (de) Diphosphonat derivate von therapeutisch wirksamen stoffen
AU683790B2 (en) Nitric esters from derivatives of 2-(2-6-dihalophenylamino) phenylacetoxyacetic acid and their preparation process
SG58291G (en) Anticonvulsant agents
BR9807785A (pt) Processo para a preparação do composto, e, composto
BR9808047B1 (pt) processo para a preparação de 2-nitroguanidinas 1,3-dissubstituìdas.
TR200001122T2 (tr) Farmasötikler olarak bifenil türevleri.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee